StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.24−0.08 (-1.09%)

Close on Nov 17, 2026Market cap $477.94MP/E –Yield –

Regenxbio cash

Cash and short-term investments held at the end of each period.

Regenxbio's cash was $105.50M at Jun 30, 2026. For fiscal 2025 it was $240.90M, down 1.6% from the year before. Over ten years it grew 1.1% a year on average. The highest annual figure on record is $849.30M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$240.90M-1.6%
FY2024Dec 31, 2024$244.90M-22.0%
FY2023Dec 31, 2023$314.10M-44.4%
FY2022Dec 31, 2022$565.20M-33.5%
FY2021Dec 31, 2021$849.30M+62.5%
FY2020Dec 31, 2020$522.50M+30.6%
FY2019Dec 31, 2019$400.00M-15.0%
FY2018Dec 31, 2018$470.60M+166.8%
FY2017Dec 31, 2017$176.40M+10.9%
FY2016Dec 31, 2016$159.00M-26.5%
FY2015Dec 31, 2015$216.37M+19201.2%
FY2014Dec 31, 2014$1.12M+0.2%
FY2013Dec 31, 2013$1.12M-48.3%
FY2012Dec 31, 2012$2.17M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$105.50M-71.0%
Q1 FY2026Mar 31, 2026$150.50M-44.8%
Q4 FY2025Dec 31, 2025$240.90M-1.6%
Q3 FY2025Sep 30, 2025$302.00M+8.4%
Q2 FY2025Jun 30, 2025$363.60M+11.1%
Q1 FY2025Mar 31, 2025$272.70M-28.3%
Q4 FY2024Dec 31, 2024$244.90M-22.0%
Q3 FY2024Sep 30, 2024$278.60M-23.6%
Q2 FY2024Jun 30, 2024$327.30M-21.2%
Q1 FY2024Mar 31, 2024$380.50M-19.6%
Q4 FY2023Dec 31, 2023$314.10M-44.4%
Q3 FY2023Sep 30, 2023$364.50M-40.9%
Q2 FY2023Jun 30, 2023$415.40M-39.1%
Q1 FY2023Mar 31, 2023$473.50M-38.1%
Q4 FY2022Dec 31, 2022$565.20M-33.5%
Q3 FY2022Sep 30, 2022$617.00M+15.7%
Q2 FY2022Jun 30, 2022$682.00M+15.0%
Q1 FY2022Mar 31, 2022$764.80M+16.5%
Q4 FY2021Dec 31, 2021$849.30M+62.5%
Q3 FY2021Sep 30, 2021$533.50M+84.1%
Q2 FY2021Jun 30, 2021$593.00M+74.8%
Q1 FY2021Mar 31, 2021$656.50M+84.1%
Q4 FY2020Dec 31, 2020$522.50M+30.6%
Q3 FY2020Sep 30, 2020$289.80M-30.5%
Q2 FY2020Jun 30, 2020$339.20M-24.6%
Q1 FY2020Mar 31, 2020$356.60M-19.7%
Q4 FY2019Dec 31, 2019$400.00M-15.0%
Q3 FY2019Sep 30, 2019$417.10M-12.2%
Q2 FY2019Jun 30, 2019$449.70M+46.8%
Q1 FY2019Mar 31, 2019$444.30M+88.4%
Q4 FY2018Dec 31, 2018$470.60M+166.8%
Q3 FY2018Sep 30, 2018$474.90M+148.5%
Q2 FY2018Jun 30, 2018$306.30M+46.9%
Q1 FY2018Mar 31, 2018$235.80M+12.5%
Q4 FY2017Dec 31, 2017$176.40M+10.9%
Q3 FY2017Sep 30, 2017$191.10M+3.4%
Q2 FY2017Jun 30, 2017$208.50M–
Q1 FY2017Mar 31, 2017$209.60M–
Q4 FY2016Dec 31, 2016$159.00M–
Q3 FY2016Sep 30, 2016$184.86M–

More Regenxbio figures

See a number that looks wrong?